Neurovascular Thrombectomy Devices/Neurothrombectomy Devices - Market Insights, Competitive Landscape, and Market Forecast - 2032

Neurovascular Thrombectomy Devices/Neurothrombectomy Devices Market by Product Type (Clot Retrievers, Stent Retrievers, Aspiration Devices, and Others), Function (Mechanical Non-aspiration and Mechanical Aspiration), Application (Peripheral Vascular Thrombectomy, Coronary Vascular Thrombectomy, and Neurovascular Thrombectomy), End-User (Hospitals & Clinics, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the rising burden of neurological disorders such as stroke, increase in cases of hypertension, diabetes, obesity, growing awareness and adoption of mechanical thrombectomy, and increase in product launches and approvals by key market players across the globe.

The neurovascular thrombectomy devices/neurothrombectomy devices market was valued at USD 849.70 million in 2024, growing at a CAGR of 6.88% during the forecast period from 2025 to 2032 to reach USD 1,434.78 million by 2032. The rising burden of neurological disorders, particularly stroke, is significantly boosting the market for neurovascular thrombectomy devices as these are the medical instruments used to remove blood clots from the blood vessels in the brain. Concurrent with this, the rise in cases of hypertension, diabetes, and obesity further exacerbates the risk of stroke and other neurological disorders. These conditions are well-established risk factors for stroke, leading to a higher incidence of acute ischemic events and, consequently, an increased demand for thrombectomy devices. However, the growing awareness and adoption of mechanical thrombectomy devices have further boosted the market. Furthermore, key market players continuously investing in research and development to introduce innovative neurovascular thrombectomy devices/neurothrombectomy devices, increased partnerships and collaborations, product launches, and approvals ensure that the market remains dynamic and innovative, during the forecast period from 2025 to 2032.

Neurovascular Thrombectomy Devices/Neurothrombectomy Devices Market Dynamics:

According to the recent data provided by the British Heart Foundation (2025), around 46 million women and 48 million men were stroke survivors.

Additionally, as per the latest data provided by the World Stroke Organization (2025), approximately, 12.2 million new strokes occur each year. Globally, one in four people over age 25 will have a stroke in their lifetime.

The escalating number of stroke cases leads to greater adoption of these devices in hospitals and specialized treatment centers, as they offer a life-saving solution for restoring blood flow. Neurovascular thrombectomy devices, which are designed to remove clots obstructing brain blood vessels, become crucial in managing acute ischemic stroke, a condition where rapid intervention is essential to minimize brain damage and improve patient outcomes. As a result, the surge in stroke cases drives the overall growth of the neurovascular thrombectomy device market, highlighting the critical role these devices play in addressing a major healthcare challenge.

Additionally, as per the data and stats provided by the World Health Organization (2024), in 2022, 1 in 8 people worldwide were living with obesity. Approximately, 2.5 billion adults aged 18 years and older were overweight, with 890 million of them living with obesity. Among adults aged 18 years and over, 43% were overweight, and 16% were living with obesity. Additionally, 37 million children under the age of 5 were overweight in 2022. The prevalence of overweight was also significant among older children and adolescents, with over 390 million individuals aged 5-19 years being overweight, including 160 million who were living with obesity.

Obesity is a well-established risk factor for several vascular diseases, including ischemic stroke, which occurs when a blood clot obstructs a blood vessel in the brain. As the global obesity rates rise, there is a corresponding increase in the incidence of stroke and other related complications. This growing patient population drives demand for neurovascular thrombectomy devices, which are used to remove blood clots from the brain and restore normal blood flow thereby escalating the overall market.

Furthermore, the successful developmental activities in the neurovascular thrombectomy devices/neurothrombectomy devices market further boost the overall market across the globe. For instance, in April 2025, Surmodics, Inc., a leading provider of medical devices and in vitro diagnostic technologies to the healthcare industry, announced the commercial launch of the Pounce(TM) XL Thrombectomy System, an advanced addition to its Pounce(TM) suite. The system was designed to enable rapid endovascular removal of acute or chronic thrombus from peripheral arteries, further strengthening the company's portfolio in vascular intervention.

Thus, the factors mentioned above are likely to boost the market of neurovascular thrombectomy devices/neurothrombectomy devices during the forecasted period.

However, the risk of complications such as vessel perforation, embolism, or damage to surrounding brain tissue and stringent regulatory concerns for product approval may hinder the future market of neurovascular thrombectomy devices/neurothrombectomy devices.

Neurovascular Thrombectomy Devices/Neurothrombectomy Devices Market Segment Analysis:

Neurovascular Thrombectomy Devices/Neurothrombectomy Devices Market by Product Type (Clot Retrievers, Stent Retrievers, Aspiration Devices, and Others), Function (Mechanical Non-aspiration and Mechanical Aspiration), Application (Peripheral Vascular Thrombectomy, Coronary Vascular Thrombectomy, and Neurovascular Thrombectomy), End-User (Hospitals & Clinics, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the product type segment of the neurovascular thrombectomy devices/neurothrombectomy devices market, clot retrievers are projected to hold a considerable market share in 2024. Clot retrievers are significantly boosting the overall market of neurovascular thrombectomy devices by revolutionizing the treatment of ischemic strokes. These devices, designed to mechanically remove blood clots from the brain's blood vessels, have enhanced the efficacy of thrombectomy procedures. Their advanced design and functionality enable more effective and reliable clot retrieval, which improves patient outcomes and increases the likelihood of complete recanalization of obstructed vessels. This has led to a broader adoption of thrombectomy as a standard treatment for acute ischemic stroke, thereby driving demand for these devices. The success of clot retrievers has also spurred innovation, leading to the development of newer, more sophisticated models with improved performance characteristics.

Additionally, clinical studies demonstrating the benefits of clot retrievers in reducing disability and mortality have increased their acceptance among healthcare professionals, further contributing to market growth. As more hospitals and stroke centers adopt these technologies, the market for neurovascular thrombectomy devices expands, driven by the increased emphasis on timely and effective stroke intervention.

This growth is also supported by ongoing research and development efforts, and other product development activities across the globe which continue to refine and enhance clot retrieval technologies, ensuring their continued relevance and effectiveness in stroke care. For instance, in June 2023, Innova Vascular received FDA clearance for two new thrombectomy devices Laguna Clot Retriever(TM) System and the Malibu Aspiration Catheter(TM) System. This system is indicated for non-surgical removal of emboli or thrombi, and/or infusing, injecting, or aspirating fluids into or from blood vessels in the peripheral vasculature.

Therefore, owing to the above-mentioned factors, the clot retriever category is expected to generate considerable revenue thereby pushing the overall growth of the global neurovascular thrombectomy devices/neurothrombectomy devices market during the forecast period.

North America is expected to dominate the overall neurovascular thrombectomy devices/neurothrombectomy devices market:

North America is expected to account for the highest proportion of the neurovascular thrombectomy devices/neurothrombectomy devices market in 2024, out of all regions. This can be ascribed to the increasing prevalence of stroke, obesity, hypertension, diabetes, and others, increased government initiatives coupled with increased awareness programs for neurovascular disease, and the presence of key market players engaged in merger, acquisition, product launches, and other market activities across the region are expected to escalate the market of neurovascular thrombectomy devices/neurothrombectomy devices.

According, to the latest data provided by the Centre for Disease Control and Prevention (2024), in the United States, a stroke occurs every 40 seconds, with more than 795,000 people experiencing a stroke annually. Of these, approximately 610,000 were first or new strokes, while around 185,000, or nearly 1 in 4, involved individuals had a previous stroke. Ischemic strokes, which result from blocked blood flow to the brain, accounted for about 87% of all stroke cases.

Additionally, as per the recent data provided by the Centre for Disease Control and Prevention (2024), nearly half of the adults in the United States, totaling 116 million, had hypertension, with the majority 92.1 million having their condition not under control.

Furthermore, as per the recent data provided by the Centre for Disease Control and Prevention (2024), approximately, 38.4 million people of all ages, representing 11.6% of the U.S. population, had diabetes.

Diabetes and hypertension are major risk factors for stroke, leading to an increased demand for effective treatments to manage and mitigate these risks. Neurovascular thrombectomy devices, which are used to remove blood clots from the brain's blood vessels, become increasingly critical as the incidence of stroke rises. This growing demand for thrombectomy procedures drives the market for these devices, as healthcare providers seek advanced tools to enhance patient outcomes and reduce the impact of strokes. Consequently, the prevalence of diabetes and hypertension directly contributes to the market expansion of neurovascular thrombectomy devices across the region.

Moreover, the increase in product development activities and ongoing research and development further escalates the market of neurovascular thrombectomy devices/neurothrombectomy devices across the region. For instance, in February 2024, Innova Vascular announced the successful early commercial use of Laguna Thrombectomy System(TM) in patients.

Therefore, the above-mentioned factors are expected to bolster the growth of the neurovascular thrombectomy devices/neurothrombectomy devices market in North America during the forecast period.

Neurovascular Thrombectomy Devices/Neurothrombectomy Devices Market Key Players:

Some of the key market players operating in the neurovascular thrombectomy devices/neurothrombectomy devices market include Stryker, Penumbra, Inc., Vesalio, LLC., Acandis GmbH, Rapid Medical, Johnson & Johnson Services Inc., Teleflex Incorporated, Medtronic, NeuroVasc Technologies, Inc., Perflow Medical, Edward LifeSciences Corporation, Terumo Corporation, Koninklijke Philips N.V., MicroVention Inc., phenox GmbH, Biomedical Solutions Inc., Ceretrieve Ltd., Anaconda Biomed SL, Genesis Medtech., Innova Vascular, and others.

Recent Developmental Activities in the Neurovascular Thrombectomy Devices/Neurothrombectomy Devices Market:

• In February 2023, Phenox Inc. received FDA 510(k) clearance for its pRESET(R) Thrombectomy Device, a minimally invasive tool designed to remove blood clots in patients with acute ischemic stroke. This minimally invasive device is designed to effectively remove blood clots from blocked brain arteries, helping to rapidly restore blood flow and minimize brain damage.
• In September 2022, Vesalio announced the CE Approval for the new NeVa NET(TM). NeVa Net(TM) micro-filtration technology is coupled with NeVa's Drop Zone(TM) technology which creates a one-of-a-kind stent retriever designed to capture every type of clot and maximize clot retention for fast and effective recanalization of ischemic tissue.

Key takeaways from the neurovascular thrombectomy devices/neurothrombectomy devices market report study:

• Market size analysis for current neurovascular thrombectomy devices/neurothrombectomy devices size (2024), and market forecast for 8 years (2025 to 2032)
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
• Key companies dominating the neurovascular thrombectomy devices/neurothrombectomy devices market.
• Various opportunities available for the other competitors in the neurovascular thrombectomy devices/neurothrombectomy devices market space.
• What are the top-performing segments in 2024? How these segments will perform in 2032?
• Which are the top-performing regions and countries in the current neurovascular thrombectomy devices/neurothrombectomy devices market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for neurovascular thrombectomy devices/neurothrombectomy devices market growth in the coming future?

Target audience who can benefit from this neurovascular thrombectomy devices/neurothrombectomy devices market report study:

• Neurovascular thrombectomy devices/neurothrombectomy devices product providers
• Research organizations and consulting companies
• Neurovascular thrombectomy devices/neurothrombectomy devices-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in neurovascular thrombectomy devices/neurothrombectomy devices
• Various end-users who want to know more about the neurovascular thrombectomy devices/neurothrombectomy devices market and the latest technological developments in the neurovascular thrombectomy devices/neurothrombectomy devices market.

Frequently Asked Questions for the Neurovascular Thrombectomy Devices/Neurothrombectomy Devices Market:

1. What are neurovascular thrombectomy devices/neurothrombectomy devices?

• Neurovascular thrombectomy devices, also known as cerebral thrombectomy devices, are used to remove or destroy blood clots in the brain region. These devices are also used in patients where pharmacological treatment has not worked effectively.

2. What is the market for neurovascular thrombectomy devices/neurothrombectomy devices?

• The neurovascular thrombectomy devices/neurothrombectomy devices market was valued at USD 849.70 million in 2024, growing at a CAGR of 6.88% during the forecast period from 2025 to 2032 to reach USD 1,434.78 million by 2032.

3. What are the drivers for the neurovascular thrombectomy devices/neurothrombectomy devices market?

• The rising burden of neurological disorders, particularly stroke, is significantly boosting the market for neurovascular thrombectomy devices as these are the medical instruments used to remove blood clots from the blood vessels in the brain. Concurrent with this, the rise in cases of hypertension, diabetes, and obesity further exacerbates the risk of stroke and other neurological disorders. These conditions are well-established risk factors for stroke, leading to a higher incidence of acute ischemic events and, consequently, an increased demand for thrombectomy devices. However, the growing awareness and adoption of mechanical thrombectomy devices have further boosted the market. Furthermore, key market players continuously investing in research and development to introduce innovative neurovascular thrombectomy devices/neurothrombectomy devices, increased partnerships and collaborations, product launches, and approvals ensure that the market remains dynamic and innovative, during the forecast period from 2025 to 2032.

4. Who are the key players operating in the neurovascular thrombectomy devices/neurothrombectomy devices market?

• Some of the key market players operating in the neurovascular thrombectomy devices/neurothrombectomy devices market include Stryker, Penumbra, Inc., Vesalio, LLC., Acandis GmbH, Rapid Medical, Johnson & Johnson Services Inc., Teleflex Incorporated, Medtronic, NeuroVasc Technologies, Inc., Perflow Medical, Edward LifeSciences Corporation, Terumo Corporation, Koninklijke Philips N.V., MicroVention Inc., phenox GmbH, Biomedical Solutions Inc., Ceretrieve Ltd., Anaconda Biomed SL, Genesis Medtech, Innova Vascular, and others.

5. Which region has the highest share in the neurovascular thrombectomy devices/neurothrombectomy devices market?

• North America is expected to account for the highest proportion of the neurovascular thrombectomy devices/neurothrombectomy devices market in 2024, out of all regions. This can be ascribed to the increasing prevalence of stroke, obesity, hypertension, diabetes, and others, increased government initiatives coupled with increased awareness programs for neurovascular disease, and the presence of key market players engaged in merger, acquisition, product launches, and other market activities across the region are expected to escalate the market of neurovascular thrombectomy devices/neurothrombectomy devices.